Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial
Key Takeaways
- Wegovy (semaglutide) is approved for chronic weight management. Mounjaro (tirzepatide) is approved for type 2 diabetes.
- The comparison comes up in search because both produce weight loss, but they are licensed for different conditions.
- For weight loss specifically, the on-label tirzepatide option is Zepbound, not Mounjaro.
- Tirzepatide outperforms semaglutide on weight loss endpoints; semaglutide has stronger cardiovascular outcomes data.
- Patients with both diabetes and obesity have the most flexibility and often end up on Mounjaro, which covers both clinically.
Direct answer
Wegovy is the obesity label for semaglutide; Mounjaro is the diabetes label for tirzepatide. The comparison crosses indications, which makes it useful only in specific circumstances: typically patients with both type 2 diabetes and obesity, or patients trying to understand whether the Mounjaro they have heard about for weight loss is the same as Zepbound. For weight loss without diabetes, the right comparison is Wegovy vs Zepbound. For diabetes management, the right comparison is Ozempic vs Mounjaro.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →Table of contents
- Why this comparison shows up
- What each drug is actually for
- The Mounjaro-for-weight-loss question
- How tirzepatide and semaglutide compare on weight loss endpoints
- How they compare on diabetes endpoints
- Cardiovascular outcomes: where Wegovy leads
- Insurance routing in 2026
- Pricing breakdown by access scenario
- Side effects at top doses
- The patient with both conditions: how to choose
- The contrary view: why some patients want Mounjaro specifically
- Decision framework
- FAQ
- Sources
Why this comparison shows up
Search-volume data shows that "Wegovy vs Mounjaro" is one of the highest-frequency GLP-1 comparison queries. Reasons:
- Mounjaro's weight-loss reputation. Before Zepbound launched in November 2023, patients seeking tirzepatide for weight loss received Mounjaro off-label. The brand became culturally associated with weight loss despite its diabetes-only label.
- The Zepbound recognition gap. Zepbound is the newer brand and less well-known in lay discourse. Patients who have heard about "the new GLP-1 for weight loss" sometimes know it as Mounjaro.
- Cost arbitrage history. Mounjaro was cheaper than Wegovy for some insured patients in 2022-2024 due to diabetes coverage policies. The off-label cost advantage drove the comparison even when the patient did not have diabetes.
- Telehealth marketing. Telehealth platforms sometimes referenced both products together without clearly delineating indications.
The cleaner question for most patients:
| What you actually want | What you should be comparing |
|---|---|
| Weight loss without diabetes | Wegovy vs Zepbound |
| Type 2 diabetes management | Ozempic vs Mounjaro |
| Weight loss with diabetes | Mounjaro vs Ozempic (with weight-loss endpoint emphasis) |
| Sleep apnea with obesity | Zepbound (the only on-label drug) |
| Cardiovascular protection with obesity | Wegovy (the only on-label drug) |
What each drug is actually for
| Wegovy | Mounjaro | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual receptor agonist |
| Initial FDA approval | June 2021 | May 2022 |
| Primary indication | Chronic weight management (BMI 30+, or 27+ with comorbidity) | Type 2 diabetes |
| Secondary indication | MACE reduction in obesity with established CVD | None (no obesity, OSA, or CV indication) |
| Same-molecule counterpart | Ozempic (semaglutide for T2D) | Zepbound (tirzepatide for obesity and OSA) |
| Maximum dose | 2.4 mg/week | 15 mg/week |
| Dose options | 0.25, 0.5, 1, 1.7, 2.4 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Pen format | Single-use disposable | Single-use disposable |
The Mounjaro-for-weight-loss question
The most common reason people search "Wegovy vs Mounjaro" is to figure out whether Mounjaro is a better weight-loss option. Honest answer:
- Tirzepatide produces more weight loss than semaglutide at top doses. SURMOUNT-5 confirmed this with mean weight loss of 20.2% vs 13.7% over 72 weeks.
- Tirzepatide is sold under two brand names: Mounjaro (for diabetes) and Zepbound (for obesity).
- The biology is identical between Mounjaro and Zepbound. A patient on Mounjaro 15 mg gets the same molecular effect as a patient on Zepbound 15 mg.
- The legal and insurance status of using Mounjaro for weight loss has tightened. Most payers will not authorize Mounjaro for a patient without an active T2D diagnosis.
If your goal is to access tirzepatide for weight loss, the on-label path is Zepbound. Pursuing Mounjaro off-label for weight loss is increasingly difficult and increasingly denied.
How tirzepatide and semaglutide compare on weight loss endpoints
The clinical evidence base for tirzepatide weight loss versus semaglutide weight loss:
| Trial | Drug & dose | Population | Mean weight loss | Duration |
|---|---|---|---|---|
| STEP 1 (Wilding 2021) | Semaglutide 2.4 mg | Obesity, no T2D | ~14.9% | 68 weeks |
| STEP 5 (Garvey 2022) | Semaglutide 2.4 mg | Obesity, no T2D | ~15.2% | 104 weeks |
| SURMOUNT-1 (Jastreboff 2022) | Tirzepatide 15 mg | Obesity, no T2D | ~22.5% | 72 weeks |
| SURMOUNT-2 (Garvey 2023) | Tirzepatide 15 mg | Obesity with T2D | ~15.7% | 72 weeks |
| SURMOUNT-5 (Aronne 2025) | Tirzepatide 15 mg vs Semaglutide 2.4 mg, head-to-head | Obesity, no T2D | 20.2% vs 13.7% | 72 weeks |
| SURPASS-2 (Frias 2021) | Tirzepatide 15 mg vs Semaglutide 1 mg, T2D | T2D | -11.2 kg vs -5.7 kg | 40 weeks |
Across every comparison that has been run, tirzepatide outperforms semaglutide on weight loss. The magnitude of the advantage is consistent: about 6-8 percentage points of body weight at the respective top doses for obesity, and about 5-6 kg additional weight loss at the respective top doses for diabetes.
How they compare on diabetes endpoints
For glycemic control, the on-label comparison would be Ozempic vs Mounjaro (both for T2D). Wegovy is not on-label for diabetes. But the molecule in Wegovy (semaglutide) is identical to the molecule in Ozempic, just at higher doses, so we can compare the two molecules:
| Drug and dose | A1C reduction (mean) | Source |
|---|---|---|
| Semaglutide 1 mg (Ozempic) | -1.5 to -1.8 pp | SUSTAIN program |
| Semaglutide 2 mg (Ozempic) | -2.1 pp | SUSTAIN FORTE |
| Semaglutide 2.4 mg (Wegovy) | ~ -1.6 pp (in patients with T2D in subgroup analyses) | STEP 2 (Davies 2021) |
| Tirzepatide 5 mg (Mounjaro) | -1.9 to -2.0 pp | SURPASS program |
| Tirzepatide 15 mg (Mounjaro) | -2.3 to -2.6 pp | SURPASS program |
Tirzepatide's glycemic advantage is consistent. At top doses, tirzepatide reduces A1C by approximately 0.3-0.5 percentage points more than semaglutide.
Cardiovascular outcomes: where Wegovy leads
The SELECT trial (Lincoff et al. NEJM 2023) established Wegovy's cardiovascular benefit in patients with obesity and established cardiovascular disease without diabetes:
- ~17,604 patients, mean follow-up 39.8 months
- 20% relative risk reduction in major adverse cardiovascular events
- FDA label expansion to include MACE reduction in March 2024
Mounjaro's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing. The expected readout is 2026-2027. Until then, Mounjaro carries no approved CV indication.
For a patient with type 2 diabetes plus established CVD, the cardiovascular evidence is split:
- Semaglutide (via Ozempic) has SUSTAIN-6 with 26% MACE reduction
- Tirzepatide (via Mounjaro) has no CV outcomes data yet
Many cardiologists and endocrinologists prefer semaglutide for older diabetes patients with established cardiovascular disease, even when tirzepatide would produce better glycemic outcomes. The choice depends on which endpoint matters most.
Insurance routing in 2026
Coverage paths for each drug:
Wegovy (obesity):
- Commercial plans: covered when obesity medications are on formulary; typical criteria are BMI 30+ (or 27+ with comorbidity) and 6 months documented lifestyle intervention
- Medicare Part D: not covered for obesity-only indication; covered for the CVD indication when applicable
- Medicaid: state-specific; some states cover obesity pharmacotherapy
- Off-label for diabetes: generally not covered
Mounjaro (diabetes):
- Commercial plans: typically covered with active T2D diagnosis
- Medicare Part D: covered as tier 2-3 with T2D diagnosis
- Medicaid: typically covered with T2D diagnosis
- Off-label for weight loss: increasingly denied; prior auth typically rejects without T2D diagnosis
The practical reality: getting Mounjaro covered for weight loss without diabetes is hard in 2026. Most major PBMs (CVS Caremark, OptumRx, Express Scripts) implemented stricter T2D verification through 2024-2025.
Pricing breakdown by access scenario
| Scenario | Wegovy | Mounjaro |
|---|---|---|
| List cash retail | ~$1,349/month | ~$1,069/month |
| Commercial insurance + indication match + savings card | $0-$200/month | $25/month |
| NovoCare Direct (cash, Wegovy) | $499/month any dose | Not applicable |
| Lilly Direct vials (Zepbound, same molecule as Mounjaro) | Not applicable | $349-$499/month (Zepbound vial, doses 2.5-10 mg) |
| Off-label without indication match | Generally denied or full cash | Generally denied or full cash |
For self-pay patients without diabetes, the practical cash comparison is Wegovy via NovoCare ($499/month) vs Zepbound via Lilly Direct ($349-$499/month). Mounjaro at full cash price is rarely the right answer.
Side effects at top doses
| Side effect | Wegovy 2.4 mg (STEP 1 / SURMOUNT-5) | Mounjaro 15 mg (SURPASS / SURMOUNT-1) |
|---|---|---|
| Nausea | ~40-44% | ~22-31% |
| Diarrhea | ~28-30% | ~17-23% |
| Vomiting | ~22-24% | ~10-12% |
| Constipation | ~22-24% | ~12-17% |
| Discontinuation for AE | ~7-8% | ~4-7% |
Despite tirzepatide reaching higher milligram doses, its aggregate GI side-effect profile is comparable or slightly more favorable than semaglutide at top dose. Possible mechanisms include GIP receptor modulation of nausea signaling, or slower dose escalation in SURMOUNT trials. Patients who failed semaglutide due to nausea sometimes tolerate tirzepatide.
Black-box warning on both: medullary thyroid carcinoma risk based on rodent data. Both contraindicated in patients with personal or family history of MTC or MEN 2.
The patient with both conditions: how to choose
For a patient with type 2 diabetes plus obesity, both Wegovy and Mounjaro are reasonable options. The choice depends on priority:
If glycemic control is the primary concern: Mounjaro. Stronger A1C reduction. Covered on the diabetes pathway with $25 copay typical.
If weight loss is the primary concern but coverage routes through diabetes: Mounjaro. Greater weight loss than semaglutide at top doses. Insurance covers because of T2D diagnosis. Best of both worlds in many cases.
If cardiovascular protection is the primary concern: Wegovy or Ozempic. Semaglutide has the CV outcomes data (SELECT, SUSTAIN-6). Tirzepatide does not have CV indication yet.
If long-term safety track record matters: Semaglutide-based products have been on market since 2017 (Ozempic) or 2021 (Wegovy). Tirzepatide-based products since 2022 (Mounjaro) or 2023 (Zepbound). Longer safety surveillance is on semaglutide's side.
If cost is the constraint and you have neither diabetes nor obesity-pathway coverage: Self-pay paths: Wegovy $499/month via NovoCare, or Zepbound vials $349-$499/month via Lilly Direct (for doses 2.5-10 mg).
The contrary view: why some patients want Mounjaro specifically
Patients who specifically want Mounjaro (rather than Zepbound) often have a few reasons:
Argument 1: Brand recognition and trust.
Mounjaro is the older, more established brand for tirzepatide. Some patients prefer the brand they recognize over the newer Zepbound name. The clinical effect is identical.
Argument 2: Insurance pathway leverage.
Patients with both diabetes and obesity sometimes find Mounjaro coverage easier to secure than Zepbound coverage, especially under plans that exclude obesity pharmacotherapy. The diabetes pathway provides cover when the obesity pathway is closed.
Argument 3: Pen consistency.
Patients already familiar with the Mounjaro pen prefer not to switch to a new device, even though the Zepbound pen is functionally equivalent.
Argument 4: Pharmacy availability.
Local pharmacy stocking patterns sometimes favor one brand over the other. Patients prescribed Mounjaro may have easier fulfillment than patients prescribed Zepbound, especially in markets with limited specialty pharmacy access.
The counter: if the patient does not have an active T2D diagnosis, prescribing Mounjaro creates regulatory and authorization risk. The on-label path for tirzepatide weight loss is Zepbound. Pursuing Mounjaro requires confirmed diabetes; absent diabetes, Zepbound is the cleaner option.
Decision framework
You have type 2 diabetes and want weight loss as a benefit: Mounjaro is on-label and covers both goals.
You have obesity without diabetes: Wegovy or Zepbound. Mounjaro is not on-label for you.
You have type 2 diabetes and have tried Wegovy without success: Switching to Mounjaro is reasonable; clinician will start at the lowest dose.
You have obesity and CVD: Wegovy has the FDA CV indication. Mounjaro does not. Choose Wegovy.
You have obesity and OSA: Zepbound (not Mounjaro). The OSA indication is on the Zepbound label specifically.
You want the cheapest cash-pay path for tirzepatide: Zepbound vials through Lilly Direct, not Mounjaro at full retail.
You have neither diabetes nor obesity: Neither drug is on-label for you. Reconsider whether GLP-1 therapy is the right intervention.
FAQ
What is the difference between Wegovy and Mounjaro? Different drugs (semaglutide vs tirzepatide), different mechanisms, different indications (obesity vs diabetes).
Is Mounjaro approved for weight loss? No. Tirzepatide is approved for weight loss under the brand Zepbound. Mounjaro is for diabetes.
Which produces more weight loss? Tirzepatide. In SURMOUNT-5, 20.2% vs 13.7% mean loss at 72 weeks.
Can I get Mounjaro for weight loss? Rarely, and increasingly denied by insurance. The on-label option is Zepbound.
Can I switch from Wegovy to Mounjaro? Yes, if you have T2D. Otherwise, switching from Wegovy to Zepbound is the equivalent move.
How does the cost compare? Wegovy ~$1,349/month list, $499 via NovoCare. Mounjaro ~$1,069/month list, $25 with insurance + T2D.
What is the side effect comparison? Similar profiles; tirzepatide shows numerically lower nausea at top dose.
Does either reduce cardiovascular risk? Wegovy yes (SELECT trial). Mounjaro pending (SURPASS-CVOT in progress).
What if I have both diabetes and obesity? Mounjaro often covers both bases under one prescription with diabetes coverage.
Are these the same drug? No. Different molecules.
Can I take them simultaneously? No. Combining incretin agonists is contraindicated.
Which is better for long-term maintenance? Both work as long as you take them. STEP 4 and SURMOUNT-4 showed that discontinuation leads to weight regain in both classes.
Sources
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity: STEP 1. New England Journal of Medicine. 2021.
- Davies M et al. Semaglutide 2.4 mg in Adults with Overweight or Obesity and Type 2 Diabetes: STEP 2. The Lancet. 2021.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity: SURMOUNT-1. New England Journal of Medicine. 2022.
- Garvey WT et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes: SURMOUNT-2. The Lancet. 2023.
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity: SURMOUNT-5. New England Journal of Medicine. 2025.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes: SURPASS-2. New England Journal of Medicine. 2021.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes: SELECT. New England Journal of Medicine. 2023.
- FDA. Wegovy and Mounjaro prescribing information. Most recent revisions 2024-2025.
- Centers for Medicare and Medicaid Services. Coverage of GLP-1 medications under Part D. 2025 guidance.
- American Diabetes Association. Standards of Care in Diabetes. 2026.
- Eli Lilly. Lilly Direct vial program for Zepbound. 2024 launch.
- Novo Nordisk. NovoCare Direct program. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that facilitates connections between patients, independent licensed prescribers, and U.S. pharmacies. We do not directly provide medical care, write prescriptions, or dispense medication. Clinical recommendations belong to your treating clinician.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are not equivalent to the brand-name products discussed in this article. Compounded versions are prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions and have not undergone FDA review for safety or efficacy.
Results Disclaimer. Statistical outcomes cited (SURMOUNT-5, STEP 1, SURMOUNT-1, SURPASS-2, SELECT, SUSTAIN-6) reflect controlled clinical-trial conditions and population averages. They do not predict any individual's experience. Real-world weight loss and glycemic outcomes typically run lower than published trial means.
Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. SURMOUNT, SURPASS, STEP, SUSTAIN, and SELECT are clinical trial program names of their respective sponsors. FormBlends has no commercial or sponsorship relationship with the manufacturers or trial sponsors mentioned above.